



**BASF Fine Chemicals Switzerland SA**  
Route Cantonale  
CH-1902 Evionnaz, Switzerland  
Phone: +41 (0)27 766 1 600  
Fax: +41 (0)27 766 1 660  
Website: [www.pharma-ingredients.basf.com](http://www.pharma-ingredients.basf.com)  
E-mail: [pharma-ingredients@basf.com](mailto:pharma-ingredients@basf.com)

The global **BASF** business unit Pharma Ingredients & Services produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines.

Production sites and technical service centers around the globe guarantee the customers tailor-made local support. The production sites fulfill quality standard ISO 9001 as well as the internationally valid regulations of current Good Manufacturing Practice (cGMP). They are regularly inspected by national and international supervisory authorities, for example by the American Food and Drug Administration (FDA), and are open for customer audits.

**The unit Pharma Ingredients & Services comprises the business areas Custom Synthesis, Excipients and Active Ingredients:**

**Custom Synthesis**

BASF produces customized active ingredients and advanced intermediates exclusively and in complete confidence on behalf of pharmaceutical companies. BASF's experts offer support through the drug lifecycle – from kilo laboratory to commercial production, from the early clinical phase to market launch and even when the drug becomes generic.

In 2005 BASF acquired the Swiss fine chemicals company Orgamol, which can boast over fifty years of experience and success in the field of exclusive synthesis. Thanks to this increase in know-how and further production facilities, BASF has come to offer even more comprehensive custom synthesis services. BASF is now one of the leading companies in this sector.

**Excipients**

BASF offers pharmaceutical companies a wide variety of excipients for making successful drugs from active ingredients with tremendous potential. In this way, the product spectrum fulfills all functional and regulatory requirements in regard to excipients for the production of tablets, sprays or drops – no matter how fast or where in the body the active ingredient is to be released, whether it tastes bitter or is hardly soluble. An example: Polymers from the Kollicoat® family act as a coating which protects the active ingredient inside tablets and makes them easier to take.

Moreover, BASF excipients are also suitable for entirely practical needs: They ensure that active ingredients can be processed well. Binders and disintegrants from the Kollidon® family optimize the mechanical properties of tablets while ensuring a more rapid release of the active ingredient at the same time.

**Active Ingredients**

BASF provides generic active ingredients for many therapeutic fields of application, making it the market leader for the substances caffeine, ibuprofen, pseudoephedrine and theophylline.

Refusing to take the properties of these active ingredients for granted, BASF is continuously refining them to give its customers a crucial competitive edge. For example, BASF has provided the active ingredient in the new Ibuprofen DC 85 with a protective particle coating. This ensures a sturdier formulation during further processing, simplifies production sequences and thus helps to reduce costs.